select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Chlamydia Infections-Pipeline Review, H1 2015

Chlamydia Infections-Pipeline Review, H1 2015

  • Products Id :- GMDHC6545IDB
  • |
  • Pages: 76
  • |
  • April 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chlamydia Infections-Pipeline Review, H1 2015


Global Markets Direct's, 'Chlamydia Infections-Pipeline Review, H1 2015', provides an overview of the Chlamydia Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chlamydia Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chlamydia Infections Overview 8

Therapeutics Development 9

Pipeline Products for Chlamydia Infections-Overview 9

Pipeline Products for Chlamydia Infections-Comparative Analysis 10

Chlamydia Infections-Therapeutics under Development by Companies 11

Chlamydia Infections-Therapeutics under Investigation by Universities/Institutes 12

Chlamydia Infections-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Chlamydia Infections-Products under Development by Companies 16

Chlamydia Infections-Products under Investigation by Universities/Institutes 17

Chlamydia Infections-Companies Involved in Therapeutics Development 18

Abera Bioscience AB 18

Adamis Pharmaceuticals Corporation 19

Big DNA Ltd. 20

CEL-SCI Corporation 21

Foamix Pharmaceuticals Ltd. 22

Genocea Biosciences, Inc. 23

Merck & Co., Inc. 24

Osel Inc. 25

Prokarium Ltd. 26

QureTech Bio AB 27

Chlamydia Infections-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

Ab-03-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

acALY-18-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

BDNA-003-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Biologic for Infectious Disease-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

C-31G-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CEL-1000-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

chlamydia trachomatis vaccine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

chlamydia vaccine-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

chlamydia vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

chlamydia vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

chlamydia vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

chlamydia vaccines-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Drugs to Block Virulence for Chlamydia Infections-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

GEN-001-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

minocycline Gel-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Peptides to Inhibit CPAF for Chlamydia Infections-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules for Chlamydophila Infections-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

solithromycin-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

VNI-201-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Chlamydia Infections-Recent Pipeline Updates 61

Chlamydia Infections-Dormant Projects 70

Chlamydia Infections-Product Development Milestones 71

Featured News & Press Releases 71

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 71

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 71

Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 72

Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center 73

Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

Number of Products under Development for Chlamydia Infections, H1 2015 9

Number of Products under Development for Chlamydia Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Chlamydia Infections-Pipeline by Abera Bioscience AB, H1 2015 18

Chlamydia Infections-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 19

Chlamydia Infections-Pipeline by Big DNA Ltd., H1 2015 20

Chlamydia Infections-Pipeline by CEL-SCI Corporation, H1 2015 21

Chlamydia Infections-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 22

Chlamydia Infections-Pipeline by Genocea Biosciences, Inc., H1 2015 23

Chlamydia Infections-Pipeline by Merck & Co., Inc., H1 2015 24

Chlamydia Infections-Pipeline by Osel Inc., H1 2015 25

Chlamydia Infections-Pipeline by Prokarium Ltd., H1 2015 26

Chlamydia Infections-Pipeline by QureTech Bio AB, H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Stage and Target, H1 2015 30

Number of Products by Stage and Mechanism of Action, H1 2015 32

Number of Products by Stage and Route of Administration, H1 2015 34

Number of Products by Stage and Molecule Type, H1 2015 36

Chlamydia Infections Therapeutics-Recent Pipeline Updates, H1 2015 61

Chlamydia Infections-Dormant Projects, H1 2015 70

List of Figures

Number of Products under Development for Chlamydia Infections, H1 2015 9

Number of Products under Development for Chlamydia Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 29

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 35

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Abera Bioscience AB

Adamis Pharmaceuticals Corporation

Big DNA Ltd.

CEL-SCI Corporation

Foamix Pharmaceuticals Ltd.

Genocea Biosciences, Inc.

Merck & Co., Inc.

Osel Inc.

Prokarium Ltd.

QureTech Bio AB

Chlamydia Infections Therapeutic Products under Development, Key Players in Chlamydia Infections Therapeutics, Chlamydia Infections Pipeline Overview, Chlamydia Infections Pipeline, Chlamydia Infections Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]